BioInvent International AB: Interim Report January - September 2025

About this update from Bioinvent International Ab

[{"type":"text","content":"LUND, SE / ACCESS Newswire / October 29, 2025 / BioInvent International (STO:BINV)","length":82,"tagName":"p"},{"type":"text","content":""The third quarter of 2025 marked continued momentum for BioInvent as we decided to focus on our most advanced programs BI-1206 and BI-1808. This strategic direction initiative is designed to accelerate the development of our most promising clinical assets and to focus on near to mid-term value creation." - Martin Welschof, CEO of BioInvent.","length":353,"tagName":"p"},{"type":"text","content":"EVENTS IN THE THIRD QUARTER","length":27,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Strategic changes in portfolio to accelerate lead clinical programs and enhance value creation","length":94,"tagName":"p"}]},{"val":[{"type":"text","content":"(R) Changes to the Board; Vincent Ossipow stepped down","length":54,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":148,"olType":false},{"type":"text","content":"EVENTS AFTER THE END OF THE PERIOD","length":34,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"BI-1206 Phase 2a trial started in advanced or metastatic NSCLC and uveal melanoma","length":81,"tagName":"p"}]},{"val":[{"type":"text","content":"Phase 1 clinical data for BI-1910, a TNFR2 Agonist for the treatment of solid tumors, to be presented at SITC 2025","length":114,"tagName":"p"}]},{"val":[{"type":"text","content":"Transgene and BioInvent presented translational data and updated clinical results on armed oncolytic virus BT-001 at ESMO 2025","length":126,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":321,"olType":false},{"type":"text","content":"(R)= Regulatory event","length":21,"tagName":"p"},{"type":"text","content":"FINANCIAL INFORMATIONThird quarter 2025","length":40,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Net sales SEK 3.3 (12.8) million.","length":33,"tagName":"p"}]},{"val":[{"type":"text","content":"Profit/loss after tax SEK -129.2 (-97.2) million.","length":49,"tagName":"p"}]},{"val":[{"type":"text","content":"Profit/loss after tax per share before and after dilution SEK -1.96 (-1.48)","length":75,"tagName":"p"}]},{"val":[{"type":"text","content":"Cash flow from operating activities SEK -104.0 (-97.0) million.","length":63,"tagName":"p"}]}],"tagName":"ul","bulletedList":...

More updates from Bioinvent International Ab